Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Nov 8, 2013)
  • 8-K (Oct 29, 2013)
  • 8-K (Oct 22, 2013)
  • 8-K (Oct 2, 2013)
  • 8-K (Sep 27, 2013)
  • 8-K (Sep 11, 2013)

 
Other

Allergan Finance LLC 8-K 2005

Documents found in this filing:

  1. 8-K
  2. 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant To Section 13 or 15(d) Of the Securities and Exchange Act Of 1934

 

May 13, 2005
Date of Report (Date of earliest event reported)

 

WATSON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

0-20045

 

95-3872914

(State or other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification Number)

 

 

 

 

 

311 Bonnie Circle
Corona, California
 

 

 

 

92880

(Address of principal executive
offices)

 

 

 

(Zip Code)

 

(951) 493-5300
(Registrant’s telephone number, including area code)

 

N/A
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 

Item 1.01         Entry Into A Material Definitive Agreement.

 

The Board of Directors of Watson Pharmaceuticals, Inc. (the “Company”) adopted, subject to stockholder approval, an amendment to and restatement of the Company’s 2001 Incentive Award Plan (the “Incentive Plan”), in the form of the Amendment and Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc. (the “Amended and Restated Plan”).  At the Annual Meeting of Stockholders of the Company held May 13, 2005, the Amended and Restated Plan was approved by the stockholders and became effective on May 13, 2005.  The Incentive Plan was amended and restated in part to:

 

      expand the types of awards available to include restricted stock awards, stock appreciation rights, dividend equivalents, restricted stock unit awards, deferred stock awards and stock payment awards;

 

      add specified performance criteria and provide that awards may be granted, become exercisable or be distributable upon the achievement of performance targets based on the performance criteria; and

 

      add provisions incorporating the requirements of Section 409A of the Code that are applicable to awards treated as non-qualified deferred compensation.

 

The Amended and Restated Plan does not increase the aggregate number of shares of Common Stock authorized for issuance under awards.

 

A copy of the Amended and Restated Plan is attached to the Company’s proxy statement for the 2005 Annual Meeting (the “Proxy Statement”).  For a more complete description of the material terms of the Amended and Restated Plan, reference is hereby made to the description of the Amended and Restated Plan included in the Proxy Statement.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Dated:

May 19, 2005.

WATSON PHARMACEUTICALS, INC.

 

 

 

 

 

By:

  /s/David A. Buchen

 

 

 

 

David A. Buchen

 

 

 

Senior Vice President, General Counsel
and Secretary

 

3


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki